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Background. This study was aimed at comparing angiogenesis, seen as microvessel density (MVD) in subtypes of non-Hodgkin’s
lymphoma (NHL). Methods. In this study, 64cases of NHL diagnosed over a three-year period were included along with 15 lymph
node biopsies of reactive hyperplasia. NHLs were classiﬁed using REAL classiﬁcation, and immunohistochemistry was performed
for CD34 in all cases. CD34-stained sections were evaluated for “hot spots,” where MVD was assessed and expressed as per mm2.
Appropriate statistical methods were applied. Results. There were 6 cases of well-diﬀerentiated lymphocytic lymphoma (SLL), 21
diﬀuse large B-cell lymphoma (DLBCL), 15 follicular lymphoma, 10 lymphoblastic lymphoma, 7 MALToma, and 5 peripheral
T-cell lymphoma (PTCL). Mean MVD was highest in reactive hyperplasia (191.92 ± 12.16 per mm2) compared to all NHLs.
Among NHLs, PTCL demonstrated the highest MVD (183.42±8.24) followed by DLBCL (149.91±13.68). A signiﬁcant diﬀerence
was found in MVD between reactive and individual lymphoma groups. SLL had signiﬁcantly lower MVD than other lymphoma
subtypes. Conclusion. Angiogenesis, assessed by MVD, showed signiﬁcant diﬀerences among subtypes of NHL, especially the
indolent types like SLL. The higher MVD in aggressive lymphomas like PTCL and DLBCL can potentially be utilized in targeted
therapy with antiangiogenic drugs.
1.Introduction
Angiogenesis or the process of formation of new blood
vessels exerts a crucial role in the progression and metastasis
of various tumors, including solid organ tumors and hema-
tologicmalignancies.Ofthevariousmethodstoassessangio-
genesis, microvessel density (MVD) has been studied exten-
s i v e l yi nv a r i o u st u m o r s[ 1, 2]. Recent studies have shown
enhanced angiogenesis in lymphomas, both Hodgkin’s dis-
ease and non-Hodgkin’s lymphoma (NHL) [3, 4]. The
results in NHLs have been conﬂicting in that few studies
have demonstrated higher MVD in aggressive subtypes of
NHL [4] while others have shown higher MVD in indolent
lymphomas[3].Someauthorshavealsoexploredassociation
of MVD with angiogenic factors and receptor expression [5].
Thisrecentandincreasinginterestinevaluationofangio-
genesis in NHLs arises from the availability ofantiangiogenic
therapy as a directed therapeutic tool [6]. This mode of
therapy has been tried in lymphoma as a single agent or
in combination with standard therapeutic protocols with
promising results [7].
Thepresentstudywasaimedatassessingtheangiogenesis
in the form of microvessel density in NHL along with com-
parison between various subtypes of NHLs, in view of the
present conﬂicting data on this subject.
2.MaterialsandMethods




Figure 1: Photomicrographs showing the histomorphology of MALToma ((a) H&E × 100), lymphoblastic lymphoma ((b) H&E × 200),
peripheral T-cell lymphoma ((c) H&E × 200), and diﬀuse large cell lymphoma ((d) H&E × 200).
of three years (2008–2010). The patients included 28 females
and 36 males, with active disease at stage III or IV. The
histological sections were reviewed and NHL subclassiﬁed
according to the REAL classiﬁcation system [8].
Angiogenesis was assessed using immunohistochemistry
for CD34 (Class II, Clone QBEnd 10, DAKO, Denmark)
in all the cases. Immunohistochemistry was performed
using standard protocols with streptavidin-biotin complex
technique and microwave heat-induced antigen retrieval in
citrate buﬀer (pH 6.0). The CD34-stained sections were
examined at 100x magniﬁcation to delineate “hot spots,”
that is, areas of maximal MVD. In three such hot spots in
each case, all microvessels (deﬁned as distinct CD34+ cell
or cell cluster, irrespective of lumen) were counted at 400x
magniﬁcation by two investigators independently (each ﬁeld
representinganareaof0.375mm2),andameanvalueofboth
investigators was taken. MVD was calculated and expressed
as number of microvessels permm2. For comparison, 15
lymph node biopsies with features of reactive lymphoid
hyperplasia were included and concurrently stained with
anti-CD34 antibody. MVD was calculated in a similar way
in these biopsies as well.
Statistical test (Student’s t-test) was applied to assess the
signiﬁcance of diﬀerence between various groups. A P value
of <0.05 was taken as statistically signiﬁcant.
3. Results
The subcategorization of the included cases according to
the REAL classiﬁcation is shown in Table 1. Most of the
cases were of ML, diﬀuse large cell type (32.81%) followed
by ML, follicular (23.44%) and ML, and lymphoblastic
type (15.63%). T-cell NHL comprised 7.81% of our cases
(Figure 1).
The mean MVD in lymph nodes with reactive lymphoid
hyperplasia was 191.92 (±12.16 permm2). This was signiﬁ-
cantlyhighercomparedtoallthelymphomasincludedinthis
study. Among lymphomas, the highest MVD was recorded
in peripheral T-cell lymphoma (183.42 ± 8.24 permm2)
followed by diﬀuse large B-cell lymphoma (149.91 ±
13.68 permm2) and follicular lymphoma (141.21 ± 23.33
permm2). Small lymphocytic lymphoma had the lowest
MVD (76.78 ±10.41 permm2) .T h eM V Do fv a r i o u sg r o u p s
of NHL and reactive lymphoid hyperplasia is tabulated in
Table 2 and Figures 2 and 3.
On statistical analysis (Student’s t-test), reactive lym-
phoid hyperplasia showed a signiﬁcantly higher MVD (P<
0.001) than individual NHL subgroups, except PTCL (P>
0.05). A signiﬁcant diﬀerence in MVD was also noted
between small lymphocytic lymphoma and other NHL
categories. PTCL showed a signiﬁcantly higher MVD (P<
0.05) than diﬀuse large cell lymphoma, follicular lymphoma,ISRN Hematology 3
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Figure 2: Photomicrographs of immunostained sections from cases of small lymphocytic lymphoma ((a) × 100), MALToma ((b) × 100),
lymphoblastic lymphoma ((c) × 100), and diﬀuse large cell lymphoma ((d) × 100).
(a) (b)
Figure 3: CD34-stained section of a case of reactive lymphoid hyperplasia ((a, b) × 100).4 ISRN Hematology
Table 1: Classiﬁcation of patients with NHL included in this study,
according to REAL classiﬁcation.
NHL type Number of cases Percentage (%)
ML, small lymphocytic 06 9.38
ML, follicular 15 23.44
ML, diﬀuse large cell 21 32.81
ML, lymphoblastic 10 15.63
MALTomas 07 10.94
ML, peripheral T cell 05 7.81
ML: malignant lymphoma.
Table 2: MVD in various NHL subgroups and reactive lymphoid
hyperplasia (expressed as mean micro-vessel count permm2).
NHL type MVD (permm2) mean ± SD
ML, small lymphocytic 76.78 ±10.41
ML, follicular 141.21 ±23.33
ML, diﬀuse large cell 149.91 ±13.68
ML, lymphoblastic 124.45 ±35.94
MALTomas 106.03 ±32.03
ML, peripheral T cell 183.42 ±8.24
Reactive lymphoid hyperplasia 191.92 ±12.16
ML: malignant lymphoma.
lymphoblastic lymphoma, and mucosa-associated lymphoid
tissue lymphoma (MALToma). No signiﬁcant diﬀerence in
MVD was found between other categories of non-Hodgkin’s
lymphoma.
4. Discussion
Angiogenesis is a multistep process playing a crucial role
in progression and metastasis of various tumors, including
those of visceral organs and hematolymphoid malignancies.
Angiogenesis is required by the tumor for ensuring adequate
supply of oxygen and nutrients to the proliferating tumor
cell [9]. Angiogenesis can be assessed by several methods,
including MVD, microvessel area, angiogenic molecular
quantiﬁcation within the tumor, presence of angiogenic
receptors within the tumor, measurement of angiogenic
factors within serum, and urine of patients with cancer [1,
2, 10]. Of these methods, MVD has been studied extensively
in various tumors.
The NHLs are a diverse group of lymphoproliferative
neoplasms with variable clinical behavior and prognosis.
Currently, lymphomas are classiﬁed on the basis of mor-
phology, immunology, and genetic and clinical features [8].
The clinical stage of the lymphoma is the most important
prognostic factor, apart from the histological grade (indolent
versus aggressive). In addition, various other features such
as age at diagnosis, tumor burden (measured by serum
LDH, beta2 microglobulin), tumor proliferation rate, p53
mutations, and T-cell immunophenotype have also been
shown to exert prognostic signiﬁcance in a few studies [11].
Few observational studies in the past have indicated that
angiogenesis is enhanced in lymphomas, demonstrated by
Wolf and Hubler in a hamster cheek pouch model [12]. Sub-
sequently, other authors demonstrated increased vascularity
in Hodgkin’s disease and NHL, with higher counts in high-
grade lymphomas [3, 4]. Studies exploring angiogenesis by
measurement of MVD have shown that MVD scores are the
highest in aggressive subtypes including Burkitt’s lymphoma
and PTCL and the lowest in indolent lymphomas [4]. In
contrast, a study evaluating B-cell NHLs showed higher
MVD in chronic lymphatic leukemia compared to aggressive
mantle cell and diﬀuse large cell lymphomas [3]. The
present study evaluated CD34 staining as marker of tumor
vascularity in biopsies with NHL and comparison of various
types of NHLs and reactive follicular hyperplasia. The MVD
was signiﬁcantly higher in peripheral T-cell lymphoma and
lower in small lymphocytic lymphoma. Our results are in
consonance with few of the previous studies [13, 14]. The
variability in results of various studies has been ascribed to
the range of cell surface markers used, diﬀerences in scoring
methodology, and heterogeneity of lymphoma stroma [15].
Few earlier studies have correlated MVD with expression
of angiogenic factors and receptors. In diﬀuse large B-cell
lymphomas, the association of MVD with tumor cell expres-
sionofvascularendothelialgrowthfactor(VEGF)hasshown
conﬂicting results in various studies [5, 16]. A recent study
found no signiﬁcant relationship between MVD and patient
characteristics like age, gender, stage, nodal status, and
response to treatment. The response to therapy was higher in
VEGF-negative patients than in VEGF-positive patients [17].
The increasing interest in evaluation of angiogenesis in
lymphomas stems from the availability and success of anti-
angiogenic therapy in certain solid tumors, like colorectal
cancer [6]. Anti-angiogenic drugs have demonstrated mod-
est clinical activity in lymphomas as a single agent and
have also been combined with rituximab-CHOP in upfront
treatment [7]. The promising result of anti-VEGF therapy
has opened an arena of therapeutic possibilities for patients
with NHL. The results of the present study suggest enhanced
angiogenesis in aggressive lymphomas, like peripheral T-
cell lymphomas and diﬀuse large B-cell lymphomas. On
the other hand, indolent lymphomas like small lymphocytic
lymphomas and follicular lymphomas had signiﬁcantly
lower MVD. This data can be helpful in assessing the
utilization of antiangiogenic therapy in patients with NHL.
Further studies are required to conﬁrm these results.
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